IL1B and hepatocellular carcinoma: Multiple studies demonstrate that AR drives the occurrence of HCC and is associated with the progression and prognosis of HCC.[35] However, early clinical trials of antiandrogen therapy for HCC have been disappointing without a clear clinical benefit.[36] TAMs are also abundantly recruited to HCC and acts as a key component in promoting HCC pathogenesis.[37] It will be interesting to see whether our findings of the adverse effect of ADT on PCa associated macrophages and increase in IL‐1β upon ADT also contribute to the failure of anti‐androgen therapy in HCC.